Deutsche Bank AG Acquires Shares of 529,443 Xeris Biopharma Holdings, Inc. $XERS

Deutsche Bank AG bought a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the second quarter, Holdings Channel reports. The firm bought 529,443 shares of the company’s stock, valued at approximately $4,193,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. UBS Group AG lifted its stake in Xeris Biopharma by 682.4% in the third quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock valued at $14,511,000 after buying an additional 1,554,869 shares during the period. Vanguard Group Inc. grew its position in shares of Xeris Biopharma by 13.8% during the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after buying an additional 1,358,760 shares during the period. Qube Research & Technologies Ltd increased its stake in shares of Xeris Biopharma by 67.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock valued at $14,429,000 after acquiring an additional 1,245,188 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after acquiring an additional 1,199,435 shares during the last quarter. Finally, Granahan Investment Management LLC raised its position in shares of Xeris Biopharma by 249.4% in the 4th quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock valued at $9,604,000 after acquiring an additional 873,236 shares during the period. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Stock Performance

Shares of XERS stock opened at $8.74 on Wednesday. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45. Xeris Biopharma Holdings, Inc. has a 52 week low of $5.25 and a 52 week high of $10.08. The company’s 50 day moving average price is $8.19 and its two-hundred day moving average price is $6.89. The company has a market capitalization of $1.59 billion, a P/E ratio of -79.45 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The company had revenue of $92.10 million for the quarter, compared to the consensus estimate of $90.12 million. On average, analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Barclays upped their target price on shares of Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Finally, Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Xeris Biopharma presently has an average rating of “Hold” and an average price target of $12.00.

Insider Transactions at Xeris Biopharma

In related news, insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $8.50, for a total value of $42,500.00. Following the sale, the insider owned 1,361,053 shares of the company’s stock, valued at approximately $11,568,950.50. This trade represents a 0.37% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Mcculloch sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $8.02, for a total value of $120,300.00. Following the transaction, the insider directly owned 1,676,126 shares of the company’s stock, valued at approximately $13,442,530.52. This trade represents a 0.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 271,499 shares of company stock worth $2,038,917. 4.35% of the stock is currently owned by company insiders.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.